Latest / My Life On GLP1 / S13.E5: My Life On GLP1 - Mounjaro & Fatty Liver Disease: Groundbreaking Research
Transcript
- 0:04SPEAKER_01: Welcome to my life on a GLP1 where we discuss the real life experiences taking these life-changing medications.
- 0:11SPEAKER_01: I'm Scott Johnson, and I'm here with my co-host Sarah to dive into something that's been making headlines in the GLP1 world lately.
- 0:20SPEAKER_00: Hey everyone.
- 0:22SPEAKER_00: And Scott, you're talking about the fatty liver disease breakthrough, right?
- 0:25SPEAKER_00: Because this is huge news.
- 0:27SPEAKER_01: Exactly.
- 0:29SPEAKER_01: So today we're talking about how GLP1 medications like Manjaro and ZeppBound are showing incredible promise for treating fatty liver disease.
- 0:40SPEAKER_01: And Sarah, when I say incredible, I mean the kind of results that make doctors do a double take.
- 0:46SPEAKER_00: Right.
- 0:47SPEAKER_00: So let's start with the basics for anyone who might not be familiar.
- 0:50SPEAKER_00: What exactly is fatty liver disease?
- 0:53SPEAKER_01: So fatty liver disease, or as it's now officially called, MASLD.
- 0:58SPEAKER_01: That's metabolic dysfunction associated steatotic liver disease.
- 1:03SPEAKER_00: Wow, that's a mouthful.
- 1:04SPEAKER_01: I know, right?
- 1:05SPEAKER_01: But basically, it's when your liver starts storing too much fat.
- 1:10SPEAKER_01: And Sarah, this isn't just affecting a few people.
- 1:13SPEAKER_01: We're talking about roughly thirty percent of adults worldwide having some form of this condition.
- 1:19SPEAKER_00: Thirty percent?
- 1:20SPEAKER_00: That's massive.
- 1:21SPEAKER_00: But there are different levels of severity, right?
- 1:23SPEAKER_01: Absolutely.
- 1:24SPEAKER_01: So you've got simple fat accumulation in the liver, which is concerning but manageable.
- 1:30SPEAKER_01: But then it can progress to what's called mash, metabolic dysfunction associated stetohepatitis.
- 1:37SPEAKER_01: This is where things get serious because now you have inflammation and potential scarring.
- 1:43SPEAKER_00: Mm-hmm.
- 1:43SPEAKER_00: And that's where the new research comes in, right?
- 1:45SPEAKER_00: Tell us about this Synergy Nash study, because the results sound almost too good to be true.
- 1:51SPEAKER_01: Oh Sarah, get ready for this.
- 1:53SPEAKER_01: The Synergy Nash study looked at tear zepatide, that's the active ingredient in Manjaro and Zeppound for treating mash.
- 2:01SPEAKER_01: And seventy-four percent of patients achieved resolution of their mash.
- 2:06SPEAKER_01: Seventy-four percent.
- 2:08SPEAKER_00: Wait, let me make sure I understand this correctly.
- 2:10SPEAKER_00: Seventy-four percent of patients saw their mash completely resolve?
- 2:14SPEAKER_00: How big was this study?
- 2:15SPEAKER_01: This was a substantial study, Sarah.
- 2:18SPEAKER_01: We're talking about nine hundred and sixty six adults with mash who were followed for fifty-two weeks.
- 2:24SPEAKER_01: And here's what makes it even more impressive.
- 2:28SPEAKER_01: Not only did seventy four percent achieve mash resolution with the highest dose of terzepatide, but fifty one percent achieved both mash resolution and at least one stage of fibrosis improvement.
- 2:42SPEAKER_01: That's the scarring we talked about earlier.
- 2:45SPEAKER_00: That's remarkable, so who would be a good candidate for this kind of treatment?
- 2:49SPEAKER_00: Is this something that's available to anyone with fatty liver disease?
- 2:53SPEAKER_01: Well, this study specifically looked at people with mash.
- 2:56SPEAKER_01: That's the more severe form with inflammation.
- 3:00SPEAKER_01: Currently, terzepatide is FDA approved for diabetes and weight management, but doctors can prescribe it off label for liver conditions.
- 3:10SPEAKER_01: The ideal candidates would typically be people with confirmed mash, often those who also have type 2 diabetes or obesity, since these conditions frequently go hand in hand.
- 3:22SPEAKER_00: That's incredible.
- 3:23SPEAKER_00: How does this medication actually help the liver though?
- 3:26SPEAKER_00: Is it just the weight loss?
- 3:27SPEAKER_01: Great question.
- 3:29SPEAKER_01: So weight loss is definitely part of it.
- 3:31SPEAKER_01: Losing excess weight reduces the fat burden on your liver.
- 3:36SPEAKER_01: But there's more to it.
- 3:37SPEAKER_01: These GLP1 medications also improve insulin sensitivity, reduce inflammation, and help with overall metabolic function.
- 3:47SPEAKER_00: Right, so it's like a multi-pronged approach.
- 3:49SPEAKER_00: And Scott, this has to be life-changing for people who've been struggling with traditional treatments.
- 3:54SPEAKER_01: Exactly.
- 3:55SPEAKER_01: Think about it.
- 3:57SPEAKER_01: For years, the main treatment for fatty liver disease has been diet and exercise.
- 4:02SPEAKER_01: And while those are important, they're not always enough.
- 4:06SPEAKER_01: Especially when you're dealing with underlying metabolic issues that make weight loss incredibly difficult.
- 4:13SPEAKER_00: Yeah, it's like telling someone to fix a complex engine problem with just a screwdriver.
- 4:17SPEAKER_00: You need the right tools for the job.
- 4:19SPEAKER_01: That's a perfect analogy, Sarah.
- 4:21SPEAKER_01: And now patients and their doctors have a powerful new tool.
- 4:26SPEAKER_01: But of course, this isn't a magic bullet.
- 4:29SPEAKER_01: People still need to work with their healthcare providers to monitor progress and manage any side effects.
- 4:36SPEAKER_00: Absolutely.
- 4:36SPEAKER_00: So what should people take away from this?
- 4:39SPEAKER_01: If you have fatty liver disease or mash, this research shows there's real hope.
- 4:45SPEAKER_01: Talk to your doctor about what treatment options might be right for you.
- 4:49SPEAKER_01: And remember, this is still evolving science.
- 4:52SPEAKER_01: We'll keep following the research and bringing you updates.
- 4:56SPEAKER_00: Thanks for breaking that down, Scott.
- 4:58SPEAKER_00: This really could be a game changer for so many people.
- 5:01SPEAKER_00: And everyone, remember, if this information resonated with you, be sure to share this episode with anyone who might benefit from hearing about these breakthrough treatments.
- 5:10SPEAKER_00: More so, we hope you will mash that five-star rating on our podcast, whatever platform you stream on.
- 5:16SPEAKER_00: And did you see what I did there?
- 5:18SPEAKER_00: Anyways, as we bring this episode to a close, tell us what final advice you have for our listeners, Scott.
- 5:24SPEAKER_01: More research certainly needs to happen before anyone fully understands the long term effects and optimal use of this medication specifically for liver disease.
- 5:36SPEAKER_01: However, the early results speak volumes.
- 5:39SPEAKER_01: For millions of Americans, this breakthrough provides something that has been in short supply for a long time.
- 5:47SPEAKER_01: I encourage you to stay current with the latest news, side effects, and trends on my website at my life on GLP one dot com.
- 5:57SPEAKER_01: And we want to hear from you.
- 5:59SPEAKER_01: You can send us your story or ideas for new topics.
- 6:03SPEAKER_01: Email us directly at Scott at MyLifeonGLP one dot com or Sarah with an H at MyLife on GLP one dot com.
- 6:13SPEAKER_01: I'm Scott Johnson, along with Sarah, reminding you to keep learning, keep advocating for yourself, and know that the future looks brighter than it has in a long time for people.
- 6:24SPEAKER_01: Thanks to these medications.
- 6:27SPEAKER_01: Thanks for tuning in and always remember to love your journey.